Overview of Dr. Rosen
Dr. Neal Rosen is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 38 years. He is one of 495 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
1275 York Avenue
New York, NY 10065
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
Brigham and Women's HospitalResidency, Internal Medicine, 1979 - 1982
Albert Einstein College of MedicineClass of 1979
Certifications & Licensure
NY State Medical License 1991 - 2026
MD State Medical License 1982 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer Start of enrollment: 2004 Mar 01
Publications & Presentations
PubMed
- 927 citationsReciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate CancerBrett S. Carver, Caren Chapinski, John Wongvipat, Haley Hieronymus, Yu Chen
Cancer Cell. 2011-05-17 - 420 citationsRelief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E MelanomasPiro Lito, Christine A. Pratilas, Eric W. Joseph, Madhavi Tadi, Ensar Halilovic
Cancer Cell. 2012-11-13 - 1061 citationsBRAF mutation predicts sensitivity to MEK inhibitionDavid B. Solit, Levi A. Garraway, Christine A. Pratilas, Ayana Sawai, Gad Getz
Nature. 2006-01-19
Journal Articles
- Efficacy of MEK Inhibition in Patients with Histiocytic NeoplasmsRobert J Young, Mario Lacouture, Neal Rosen, David M Hyman, Raajit Rampal, Gary A Ulaner, Benjamin H Durham, Lynn A Brody, Nature
- Synergistic Anti-Angiogenic Treatment Effects by Dual FGFR1 and VEGFR1 Inhibition in FGFR1-Amplified Breast CancerNeal Rosen, MD, Nature
Press Mentions
Mechanisms of Resistance to KRAS Inhibitors Multiple and DiverseJune 29th, 2021- Multiple Avenues Mapped for Resistance to Novel KRAS G12C InhibitorJune 24th, 2021
Ribon Therapeutics to Present at the Jefferies Virtual Healthcare ConferenceMay 26th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
